Focus on Diabetes Care

Back to articles

Another favorable CV study for an antidiabetic agent

KEY POINT

Addition of liraglutide (Victoza—Novo Nordisk) to standard of care therapy in patients with type 2 diabetes at high risk for cardiovascular (CV) events resulted in a reduced risk of adverse CV outcomes.

SOURCES

Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.

Ingelfinger JR, et al. Cardiac and renovascular complications in type 2 diabetes—is there hope? N Engl J Med. 2016;375:380–2.